组织工程市场－全球产业规模、份额、趋势、机会、预测：依材料类型、应用、最终用户、地区和竞争格局划分，2021-2031年

全球组织工程市场预计将从 2025 年的 140.2 亿美元大幅成长至 2031 年的 240.5 亿美元，复合年增长率为 9.41%。

这个交叉学科领域结合了细胞、工程材料和生物化学因子，旨在恢復或改善生物功能，其发展动力主要来自慢性疾病的日益增多和全球人口老化。此外，器官捐赠的严重短缺也大大促进了这一领域的成长，增加了对生物替代疗法的需求。根据器官捐赠网络联盟（Organ Donation Network Coalition）预测，截至2025年，“将有超过10万名候选人等待挽救生命的器官移植”，这凸显了大规模创新技术的迫切需求。

然而，由于产品核准所需的监管流程复杂且严格，该行业面临许多重大障碍。研发和长期临床试验所需的大量资金可能会抑制投资，并延缓新治疗方法的上市。因此，克服不同国际司法管辖区严格的合规标准和报销不确定性，构成了阻碍该领域快速发展的重大障碍。

市场驱动因素

3D生物列印和生物製造技术的快速发展，正从根本上改变这一领域，使复杂且功能性的组织结构能够精确地建构。这些进步克服了以往在规模化和血管生成方面面临的挑战，并使得大规模生产能够忠实模拟自然生物学的组织结构成为可能。 CollPlant Biotechnologies公司于2024年6月发布的新闻稿「CollPlant成功生物印出200cc商用尺寸的再生乳房植入」是一个很好的例证。该公司成功生物列印出200cc的再生乳房植入，标誌着软组织填充的商业性规模化应用迈出了重要一步，并引领业界走向实用且可植入的解决方案。

同时，政府和私人机构对再生医学研发投入的增加，正成为市场成长的主要驱动力。这些资金的注入对于维持高风险研究以及建造先进生物製造所需的专业基础设施至关重要。例如，英国研究与创新署（UKRI）在2024年2月发布的题为《一项新的1亿英镑基金释放生物技术的潜力》的报告中，承诺投入1亿英镑建立一个新的生物技术和生物医学中心。在全球范围内，这项投资一直保持稳定。根据再生医学联盟2024年的报告，该领域在今年上半年吸引了约109亿美元的投资，显示人们对下一代治疗方法的商业性前景仍然充满信心。

市场挑战

严格的法规结构和巨额的研发成本对全球组织工程市场的成长构成了重大挑战。生物替代疗法的开发必须符合世界卫生组织制定的严格安全性和有效性标准，这需要进行复杂而漫长的临床试验。这些苛刻的要求必然会带来巨额的资金投入，使得研发人员获得监管部门的核准成为一条耗资巨大且耗时漫长的道路。

因此，这种充满挑战的商业环境直接阻碍了行业扩张，因为它设置了准入壁垒并抑制了投资。核准时间的不确定性以及后期临床试验的高失败风险尤其影响中小企业，限制了创新所需的资金流入。根据再生医学联盟（Alliance for Regenerative Medicine）统计，2024年上半年全球再生医学领域的投资额达到109亿美元，与疫情尖峰时段相比，早期企业的资金筹措环境更加紧张。资金支持的减少迫使许多公司推迟商业化进程或终止前景看好的治疗项目，导致整体市场发展放缓。

市场趋势

用于药物筛检的「晶片器官」平台的兴起，透过提供标准化的人体组织模型，减少了对动物实验的依赖，正在革新临床前试验。这一趋势正引领产业迈向高通量商业系统，这些系统能够模拟系统性交互作用，从而进行精准的毒性分析，使药物研发人员能够儘早获得可预测的代谢数据，从而降低临床试验失败的风险。根据CN Bio于2025年10月发布的新闻稿《CN Bio发布一体化晶片器官系统》，该公司推出了“PhysioMimix Core”，这是一个整合系统，能够同时对多达288个样本进行高通量筛检，从而支持复杂的多器官实验，并加速治疗方法的检验。

将人工智慧 (AI) 整合到支架结构设计中，正在提升生物製造组织的功能品质。生成式 AI 模型被用来定义复杂的微结构，从而实现满足营养扩散和细胞活力等关键要求的支架设计，同时也能透过自适应製造系统进行即时参数调整。例如，在 Bioengineer.org 于 2025 年 9 月发表的报导「AI 将印表机转变为组织工程的协作工具」的文章中，研究人员开发了一种名为「GRACE」的 AI 驱动的体积生物列印系统。该系统利用生成式模型合成最佳组织设计，并在列印过程中自适应地纠正缺陷，从而能够创建以前无法实现的具有活性的血管结构。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球组织工程市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依材料类型（合成材料、生物来源材料、其他）
  • 依应用领域（整形外科、肌肉骨骼系统/脊椎、神经科、心臟科、皮肤/覆盖组织、其他）
  • 依最终用户（医院、癌症研究中心、学术/研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美组织工程市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲组织工程市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区组织工程市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲组织工程市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲组织工程市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球组织工程市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zimmer Biomet Holdings Inc.
• Stryker Corporation Holdings
• 3D BioFibR Inc.
• Integra LifeSciences Corporation
• CollPlant Biotechnologies Ltd.
• AbbVie Inc.
• Becton, Dickinson and Company
• Athersys, Inc.
• BioTissue Holding Inc.
• Japan Tissue Engineering Co., Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Tissue Engineering Market is projected to expand significantly, growing from USD 14.02 Billion in 2025 to USD 24.05 Billion by 2031, representing a CAGR of 9.41%. This multidisciplinary field, which combines cells, engineering materials, and biochemical factors to restore or improve biological functions, is largely propelled by the increasing prevalence of chronic diseases and an aging global population. Furthermore, the critical shortage of donor organs serves as a major catalyst for growth, driving the need for biological substitutes; according to the 'United Network for Organ Sharing', in '2025', 'more than 100,000 candidates are currently awaiting life-saving organ transplants', underscoring the urgent demand for scalable innovations.

However, the industry faces substantial obstacles due to the complex and stringent regulatory pathways necessary for product approval. The immense financial outlay required for research, development, and protracted clinical trials can discourage investment and postpone the launch of new therapies. Consequently, maneuvering through these rigorous compliance standards and reimbursement uncertainties across various international jurisdictions presents a significant barrier that could hinder the sector's rapid expansion.

Market Driver

Rapid technological progress in 3D bioprinting and bio-fabrication is fundamentally transforming the sector by facilitating the precise creation of complex, functional tissue structures. These advancements resolve historical issues related to scalability and vascularization, enabling the production of large-scale tissue constructs that closely emulate natural biology. A prime example occurred in June 2024, when CollPlant Biotechnologies announced in their 'CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants' press release that they had successfully bioprinted 200cc regenerative breast implants, marking a pivotal step toward commercial scalability for soft tissue reinforcement and moving the industry toward viable, implantable solutions.

Simultaneously, increasing government and private funding for regenerative medicine R&D is acting as a primary driver for market growth. This capital infusion is crucial for sustaining high-risk research and building the specialized infrastructure needed for advanced bio-manufacturing. For instance, according to UK Research and Innovation's 'New £100m fund will unlock the potential of engineering biology' announcement in February 2024, the organization committed £100 million to establish new mission hubs for engineering biology and biomedicine. Globally, this financial commitment remains strong; the Alliance for Regenerative Medicine reported in 2024 that the sector attracted roughly $10.9 billion in investment during the first half of the year, indicating continued confidence in the commercial prospects of these next-generation therapies.

Market Challenge

Stringent regulatory frameworks and the exorbitant costs associated with research and development pose a major challenge to the growth of the Global Tissue Engineering Market. Creating biological substitutes demands compliance with rigorous safety and efficacy standards set by international health authorities, which necessitates complex and extended clinical trials. These strict requirements inevitably result in immense financial expenditures, rendering the path to regulatory approval both capital-intensive and time-consuming for developers.

As a result, this difficult operating environment directly hinders industry expansion by establishing barriers to entry and discouraging investment. The uncertainty regarding approval timelines and the high risk of failure in late-stage trials limit the capital flow necessary for innovation, particularly affecting small and medium-sized enterprises. According to the 'Alliance for Regenerative Medicine', in '2024', 'global investment in the regenerative medicine sector reached USD 10.9 billion in the first half of the year, reflecting a constrained funding landscape for early-stage companies compared to pandemic-era peaks'. This decline in financial support compels many firms to postpone commercialization efforts or discontinue promising therapeutic programs, effectively decelerating overall market progression.

Market Trends

The rise of Organ-on-a-Chip platforms for drug screening is revolutionizing preclinical testing by offering standardized human tissue models that reduce dependence on animal studies. This trend steers the sector toward high-throughput commercial systems that simulate systemic interactions for precise toxicity profiling, allowing pharmaceutical developers to mitigate clinical trial failures by securing predictive metabolic data early. According to CN Bio's 'CN Bio launches all-in-one Organ-on-a-chip system' press release in October 2025, the company introduced the PhysioMimix Core, a unified system capable of high-throughput screening for up to 288 samples simultaneously, thereby enabling complex multi-organ experiments and accelerating therapeutic validation.

The integration of Artificial Intelligence into scaffold architecture design is enhancing the functional quality of bio-fabricated tissues. Generative AI models are being employed to define complex micro-architectures, ensuring that scaffolds satisfy critical requirements for nutrient diffusion and cell viability while enabling adaptive manufacturing systems to adjust parameters in real-time. For example, according to the 'AI Transforms Printers into Collaborative Tools for Tissue Engineering' article by Bioengineer.org in September 2025, researchers created 'GRACE', an AI-driven volumetric bioprinting system that utilizes generative models to synthesize optimal tissue designs and adaptively correct defects during printing, facilitating the creation of viable, vascularized structures that were previously unattainable.

Key Market Players

• Zimmer Biomet Holdings Inc.
• Stryker Corporation Holdings
• 3D BioFibR Inc.
• Integra LifeSciences Corporation
• CollPlant Biotechnologies Ltd.
• AbbVie Inc.
• Becton, Dickinson and Company
• Athersys, Inc.
• BioTissue Holding Inc.
• Japan Tissue Engineering Co., Ltd

Report Scope

In this report, the Global Tissue Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Engineering Market, By Material Type

• Synthetic Materials
• Biologically Derived Materials
• Others

Tissue Engineering Market, By Application

• Orthopedics
• Musculoskeletal & Spine
• Neurology
• Cardiology
• Skin & Integumentary
• Others

Tissue Engineering Market, By End User

• Hospitals
• Cancer Research Centers
• Academic and Research Institutes
• Others

Tissue Engineering Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Engineering Market.

Available Customizations:

Global Tissue Engineering Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Engineering Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Material Type (Synthetic Materials, Biologically Derived Materials, Others)
  • 5.2.2. By Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology, Skin & Integumentary, Others)
  • 5.2.3. By End User (Hospitals, Cancer Research Centers, Academic and Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Tissue Engineering Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Material Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tissue Engineering Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Material Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Tissue Engineering Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Material Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Tissue Engineering Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Material Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Tissue Engineering Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Material Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tissue Engineering Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Material Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Tissue Engineering Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Material Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Tissue Engineering Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Material Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Tissue Engineering Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Material Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Tissue Engineering Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Material Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Tissue Engineering Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Material Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tissue Engineering Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Material Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Tissue Engineering Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Material Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Tissue Engineering Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Material Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Tissue Engineering Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Material Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Tissue Engineering Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Material Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Tissue Engineering Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Material Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tissue Engineering Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Material Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Tissue Engineering Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Material Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Tissue Engineering Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Material Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Tissue Engineering Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Material Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tissue Engineering Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Material Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Tissue Engineering Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Material Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Tissue Engineering Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Material Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tissue Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zimmer Biomet Holdings Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Stryker Corporation Holdings
• 15.3. 3D BioFibR Inc.
• 15.4. Integra LifeSciences Corporation
• 15.5. CollPlant Biotechnologies Ltd.
• 15.6. AbbVie Inc.
• 15.7. Becton, Dickinson and Company
• 15.8. Athersys, Inc.
• 15.9. BioTissue Holding Inc.
• 15.10. Japan Tissue Engineering Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer